Certara (NASDAQ:CERT) Shares Gap Up on Analyst Upgrade

Shares of Certara, Inc. (NASDAQ:CERT - Get Free Report) gapped up prior to trading on Friday after KeyCorp raised their price target on the stock from $15.00 to $18.00. The stock had previously closed at $10.51, but opened at $11.84. KeyCorp currently has an overweight rating on the stock. Certara shares last traded at $12.02, with a volume of 2,155,196 shares trading hands.

Several other equities analysts also recently commented on CERT. Stephens reiterated an "overweight" rating and issued a $17.00 price objective on shares of Certara in a report on Thursday, February 27th. TD Cowen began coverage on shares of Certara in a research report on Thursday, February 27th. They set a "buy" rating and a $16.00 price target on the stock. Robert W. Baird raised their target price on shares of Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a report on Friday, April 11th. Barclays reduced their price target on Certara from $13.00 to $11.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Finally, William Blair reaffirmed a "market perform" rating on shares of Certara in a report on Thursday, February 27th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $15.17.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Blue Trust Inc. raised its stake in Certara by 20.9% during the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock worth $56,000 after buying an additional 822 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Certara by 3.6% during the 4th quarter. The Manufacturers Life Insurance Company now owns 23,720 shares of the company's stock worth $253,000 after purchasing an additional 823 shares in the last quarter. Wells Fargo & Company MN grew its position in Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock valued at $34,000 after purchasing an additional 1,047 shares during the period. Bank of Montreal Can grew its position in Certara by 9.1% in the 4th quarter. Bank of Montreal Can now owns 19,943 shares of the company's stock valued at $212,000 after purchasing an additional 1,670 shares during the period. Finally, Versant Capital Management Inc increased its stake in Certara by 218.8% during the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock valued at $27,000 after purchasing an additional 1,866 shares in the last quarter. Institutional investors own 73.96% of the company's stock.

Certara Price Performance

The stock has a market capitalization of $2.18 billion, a P/E ratio of -67.40, a price-to-earnings-growth ratio of 9.29 and a beta of 1.64. The business's 50 day simple moving average is $11.62 and its two-hundred day simple moving average is $11.41. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.